Insulin‑like growth factor‑II mRNA‑binding protein 3 predicts a poor prognosis for colorectal adenocarcinoma

Lin,Lijuan; Zhang,Jinhui; Wang,Yan; Ju,Weiei; Ma,Yibing; Li,Lina; Chen,Litian

doi:10.3892/ol.2013.1458

Insulin‑like growth factor‑II mRNA‑binding protein 3 predicts a poor prognosis for colorectal adenocarcinoma

Authors:
- Lijuan Lin
- Jinhui Zhang
- Yan Wang
- Weiei Ju
- Yibing Ma
- Lina Li
- Litian Chen
View Affiliations

Affiliations: Department of Medicine Imaging, Eastern Liaoning University College of Medicine, Dandong, Liaoning 118000, P.R. China, Department of Pathology, Dandong Centre Hospital, Dandong, Liaoning 118000, P.R. China, Department of Pediatrics, Tianjin First Centre Hospital, Tianjin 310092, P.R. China, Department of Liver Transplantation Surgery, Xin Hua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, P.R. China
Published online on: July 12, 2013 https://doi.org/10.3892/ol.2013.1458
Pages: 740-744

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Insulin‑like growth factor‑II mRNA‑binding protein 3 (IMP3) has been recently identified as a marker of aggressive behavior in several types of tumors. The aim of the present study was to detect the expression of the IMP3 protein in colorectal adenocarcinoma (CRA) and to identify a correlation with the clinicopathological features of the disease. IMP3 was evaluated in 186 samples of CRA using immunohistochemical methods. The correlation between IMP3 expression and the clinicopathological features of colorectal cancer was evaluated by the χ2 and Fisher's exact tests. Survival rates were calculated using the Kaplan‑Meier method and the correlation between IMP3 protein expression and the prognosis of patients with CRA was analyzed using Cox analysis. Of the 186 adjacent normal mucosa (ANM) cases, the 22 that exhibited dysplasia demonstrated weak IMP3 expression and the 164 without dysplasia showed no expression. Of the 186 CRA cases, immunohistochemical staining for IMP3 was observed in 143 cases (76.9%). A comparison of IMP3 expression between the CRA and ANM samples revealed stronger immunohistochemical reactivity in the CRA tissues (P<0.01). High IMP3 expression was associated with differentiation, lymphoid metastasis, TNM stage, Ki‑67 labeling index and a poor patient outcome (P<0.05). In the multivariate analysis, IMP3 emerged as an independent predictor of survival. The present study demonstrated that IMP3 is able to promote the aggressiveness of cancer behavior, resulting in a poor prognosis for patients with CRA. Consequently, IMP3 may be regarded as a novel proliferation and prognostic indicator for patients with CRA.

View Figures

View References

1	Lim SC and Hong R: Programmed cell death 4 (Pdcd4) expression in colorectal adenocarcinoma: Association with clinical stage. Oncol Lett. 2:1053–1057. 2011.PubMed/NCBI
2	Alwan A: World Health Organization. Disaster Med Public Health Prep. 1:7–8. 2007. View Article : Google Scholar
3	Ikenberg K, Fritzsche FR, Zuerrer-Haerdi U, et al: Insulin-like growth factor II mRNA binding protein 3 (IMP3) is overexpressed in prostate cancer and correlates with higher Gleason scores. BMC Cancer. 10:3412010. View Article : Google Scholar : PubMed/NCBI
4	Mentrikoski MJ, Ma L, Pryor JG, et al: Diagnostic utility of IMP3 in segregating metastatic melanoma from benign nevi in lymph nodes. Mod Pathol. 22:1582–1587. 2009. View Article : Google Scholar : PubMed/NCBI
5	Hoffmann NE, Sheinin Y, Lohse CM, et al: External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. Cancer. 112:1471–1479. 2008. View Article : Google Scholar : PubMed/NCBI
6	Jiang Z, Chu PG, Woda BA, et al: Combination of quantitative IMP3 and tumor stage: a new system to predict metastasis for patients with localized renal cell carcinomas. Clin Cancer Res. 14:5579–5584. 2008. View Article : Google Scholar : PubMed/NCBI
7	Schaeffer DF, Owen DR, Lim HJ, et al: Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) overexpression in pancreatic ductal adenocarcinoma correlates with poor survival. BMC Cancer. 10:592010. View Article : Google Scholar : PubMed/NCBI
8	Mhawech-Fauceglia P, Herrmann FR, Rai H, et al: IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma. Am J Clin Pathol. 133:899–908. 2010. View Article : Google Scholar : PubMed/NCBI
9	Lu D, Yang X, Jiang NY, et al: IMP3, a new biomarker to predict progression of cervical intraepithelial neoplasia into invasive cancer. Am J Surg Pathol. 35:1638–1645. 2011. View Article : Google Scholar : PubMed/NCBI
10	Hammer NA, Hansen Tv, Byskov AG, et al: Expression of IGF-II mRNA-binding proteins (IMPs) in gonads and testicular cancer. Reproduction. 130:203–212. 2005. View Article : Google Scholar
11	Li C, Rock KL, Woda BA, et al: IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16(INK4a) expression. Mod Pathol. 20:242–247. 2007. View Article : Google Scholar : PubMed/NCBI
12	Gress TM, Müller-Pillasch F, Geng M, et al: A pancreatic cancer-specific expression profile. Oncogene. 13:1819–1830. 1996.PubMed/NCBI
13	Nielsen J, Christiansen J, Lykke-Andersen J, et al: A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol. 19:1262–1270. 1999.PubMed/NCBI
14	Tosun Yildirim H and Sentürk N: Analysis of IMP3 expression in prostate adenocarcinomas. Turk Patoloji Derg. 28:128–133. 2012.PubMed/NCBI
15	Liao B, Hu Y, Herrick DJ and Brewer G: The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J Biol Chem. 280:18517–18524. 2005. View Article : Google Scholar
16	Jeng YM, Wang TH, Lu SH, et al: Prognostic significance of insulin-like growth factor II mRNA-binding protein 3 expression in gastric adenocarcinoma. Br J Surg. 96:66–73. 2009. View Article : Google Scholar : PubMed/NCBI
17	Xu C, Jiang XZ, Zhao HF, et al: The applicability of Ki-67 marker for renal epithelioid angiomyolipoma: experience of ten cases from a single center. Neoplasma. 60:209–214. 2013. View Article : Google Scholar : PubMed/NCBI
18	Wang L, Li HG, Xia ZS, et al: IMP3 is a novel biomarker to predict metastasis and prognosis of gastric adenocarcinoma: a retrospective study. Chin Med J (Engl). 123:3554–3558. 2010.PubMed/NCBI
19	Sitnikova L, Mendese G, Liu Q, et al: IMP3 predicts aggressive superficial urothelial carcinoma of the bladder. Clin Cancer Res. 14:1701–1706. 2008. View Article : Google Scholar : PubMed/NCBI
20	Yaniv K, Fainsod A, Kalcheim C and Yisraeli JK: The RNA-binding protein Vg1 RBP is required for cell migration during early neural development. Development. 130:5649–5661. 2003. View Article : Google Scholar : PubMed/NCBI
21	Yantiss RK, Cosar E and Fischer AH: Use of IMP3 in identification of carcinoma in fine needle aspiration biopsies of pancreas. Acta Cytol. 52:133–138. 2008. View Article : Google Scholar : PubMed/NCBI
22	Okada K, Fujiwara Y, Nakamura Y, et al: Oncofetal protein, IMP-3, a potential marker for prediction of postoperative peritoneal dissemination in gastric adenocarcinoma. J Surg Oncol. 105:780–785. 2012. View Article : Google Scholar : PubMed/NCBI
23	Wachter DL, Kristiansen G, Soll C, et al: Insulin-like growth factor II mRNA-binding protein 3 (IMP3) expression in hepatocellular carcinoma. A clinicopathological analysis with emphasis on diagnostic value. Histopathology. 60:278–286. 2012. View Article : Google Scholar